Adaptin Bio
PublicAdaptin Bio is now publicly traded
The data on this page reflects Adaptin Bio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Convertible Debt
Dec 22, 2025
Total Funding Raised
$1.65M
Company Overview
Adaptin Bio has raised $1.65M. It was founded in 2021.
Adaptin Bio Operating Corporation is a biotechnology company that develops novel therapies for oncology and central nervous system disorders with improved drug delivery to the brain and other tissues.
AI Layer
Non-AI
Adaptin Bio Comparables
Compare Adaptin Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Altido Therapeutics | 85% | |
| Mesenkia Therapeutics AB | 81% | |
| NovalGen | 74% |
For institutional investors. Book with your work email.
Adaptin Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Dec 22, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Adaptin Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.